iCell Gene Therapeutics
CD4 CAR T cells(iCell Gene Therapeutics)은 FRα 표적 세포·유전자 치료로, T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targetable modulator of JAK-STAT signaling. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, tr.
FRα
T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma
Active
CAR T cells in a preclinical, humanized mouse model
retroviral therapy (ART)
humanized mouse model
novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, tr
targetable modulator of JAK-STAT signaling
cytokine release syndrome
biomarker and therapeutic target in CAR T cell-associated neurotoxicity
resistance to CAR-T treatment, underscoring the importance of optimizing CAR-T design to enhance responsiveness
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
iCell Gene Therapeutics
CD4 CAR T cells(iCell Gene Therapeutics)은 FRα 표적 세포·유전자 치료로, T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targetable modulator of JAK-STAT signaling. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, tr.
FRα
T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma
Active
CAR T cells in a preclinical, humanized mouse model
retroviral therapy (ART)
humanized mouse model
novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, tr
targetable modulator of JAK-STAT signaling
cytokine release syndrome
biomarker and therapeutic target in CAR T cell-associated neurotoxicity
resistance to CAR-T treatment, underscoring the importance of optimizing CAR-T design to enhance responsiveness
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.